Bone Biologics (BBLG) vs Regentis Biomaterials (RGNT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Regentis Biomaterials is the larger company by market cap ($11.9 million vs $1.3 million), about 9.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBLG | RGNT |
|---|---|---|
| Share price | $0.4691 | $1.70 |
| Market cap | $1.29M | $11.94M |
| 1-day change | -3.77% | +4.29% |
| YTD return | — | -74.78% |
| EPS (TTM) | $-1.34 | $-2.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.76 | $15.50 |
| 52-week low | $0.428 | $1.23 |
| Distance from 52-week high | -83.00% | -89.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +2500.72% | +488.24% |
| Average volume | 378.20K | 76.78K |
| Shares outstanding | 2.76M | 7.02M |
| Employees | 2 | — |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regentis Biomaterials is about 9.2 times larger than Bone Biologics by market value ($11.94M vs $1.29M).
About Bone Biologics
BBLG stock →Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration.
Healthcare · Biotechnology · 2 employees
About Regentis Biomaterials
RGNT stock →Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee.
Healthcare · Medical Instruments & Supplies
BBLG vs RGNT FAQ
Which is bigger, Bone Biologics or Regentis Biomaterials?
Regentis Biomaterials (RGNT) is larger, with a market capitalization of $11.94M compared with $1.29M for Bone Biologics (BBLG).
Are Bone Biologics and Regentis Biomaterials in the same industry?
Both are in the Healthcare sector, but in different industries: Biotechnology for Bone Biologics and Medical Instruments & Supplies for Regentis Biomaterials.